Patents by Inventor Reinhard Ebner
Reinhard Ebner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220177954Abstract: A nucleic acid probe for hybridization to chromosomal DNA comprises at least two different nucleic acid molecules from the same chromosomal region of CHD1, where the nucleic acid molecules are present in different proportions from each other. A method of treating prostate cancer in a subject is also provided based on an assessment of whether the subject's prostate cancer is associated with CHD1 deficiency.Type: ApplicationFiled: December 3, 2021Publication date: June 9, 2022Inventor: Reinhard Ebner
-
Publication number: 20180135137Abstract: The present embodiments relate to nucleic acid probes for detecting PTEN, ZBTB20-LSAMP, and LSAMP mutations. The nucleic acid probes are particularly useful for detecting deletions in the PTEN and LSAMP genes as diagnostics for prostate cancer, especially aggressive forms of prostate cancer for which treatment is indicated. The probes are particularly useful for in situ hybridization to chromosomes present in tissue samples.Type: ApplicationFiled: January 4, 2018Publication date: May 17, 2018Applicant: Cytotest, Inc.Inventors: Reinhard Ebner, Hua ZOU, Chi-Chung Cheng
-
Publication number: 20170218398Abstract: Methods and compositions for selectively targeting cancerous cells for genetic manipulation based on cancer specific sequence motifs (CSSMs), which are formed as a result of chromosomal rearrangement, and cells produced by said methods.Type: ApplicationFiled: January 30, 2017Publication date: August 3, 2017Inventors: Markus Alexander Brown, Reinhard Ebner
-
Publication number: 20170191131Abstract: A detectably labeled DNA FISH probe comprises detectably-labeled nucleic acid molecules from the 8p11.23 chromosomal region and from the 2q35 chromosomal region. The probe is a FISH probe capable of detecting a fusion between the FGFR1 and FN1 genes. A patient having a disease associated with a FN1-FGFR1 gene fusion may be treated by: detecting translocation of a portion of the FGFR1 gene to the FN1 gene using chromosomal FISH probes, and treating a patient with said translocation and gene fusion with 1) a drug which inhibits FGF 2) a drug which inhibits FGFR1, and/or a 3) drug which targets a signaling pathway associated with FGFR1.Type: ApplicationFiled: January 4, 2017Publication date: July 6, 2017Applicant: Cytotest, Inc.Inventors: Reinhard Ebner, Hua ZOU, Chi-Chung Cheng
-
Publication number: 20140322302Abstract: Therapeutic peptides having guanylyl cyclase C agonist activity are disclosed. The therapeutic peptides are analogues of the E. coli STa peptide with non-natural amino acid, isosteric or D-amino acid substituents. The therapeutic peptides are useful in the treatment of chronic ideopathic constipation, inflammatory bowel disease, and other diseases. Pharmaceutical compositions comprising the therapeutic peptides are also disclosed.Type: ApplicationFiled: May 11, 2014Publication date: October 30, 2014Applicant: COMBIMAB, INCInventors: Henry Wolfe, Reinhard Ebner
-
Patent number: 8748575Abstract: Therapeutic peptides having guanylyl cyclase C agonist activity are disclosed. The therapeutic peptides are analogues of the E. coli STa peptide with non-natural amino acid, isosteric or D-amino acid substituents. The therapeutic peptides are useful in the treatment of chronic ideopathic constipation, inflammatory bowel disease, and other diseases. Pharmaceutical compositions comprising the therapeutic peptides are also disclosed.Type: GrantFiled: June 8, 2011Date of Patent: June 10, 2014Assignee: Combimab, Inc.Inventors: Henry Wolfe, Reinhard Ebner
-
Publication number: 20140038881Abstract: Therapeutic peptides having guanylyl cyclase C agonist activity are disclosed. The therapeutic peptides are analogues of the E. coli STa peptide with non-natural amino acid, isosteric or D-amino acid substituents. The therapeutic peptides are useful in the treatment of chronic ideopathic constipation, inflammatory bowel disease, and other diseases. Pharmaceutical compositions comprising comprising the therapeutic peptides are also disclosed.Type: ApplicationFiled: June 8, 2011Publication date: February 6, 2014Applicant: COMBIMAB, INCInventors: Henry Wolfe, Reinhard Ebner
-
Patent number: 8303951Abstract: The present invention relates to a Neutrokine-alpha antibody and a process for producing a Neutrokine-alpha antibody. The invention further relates to screening methods for identifying compounds that inhibit or enhance the action of Neutrokine-alpha. Also provided are diagnostic methods for detecting autoimmune disorders and therapeutic methods for treating autoimmune disorders using a Neutrokine-alpha antibody.Type: GrantFiled: February 26, 2009Date of Patent: November 6, 2012Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni
-
Patent number: 8231873Abstract: The present invention relates to a Neutrokine-alpha antibody and a process for producing a Neutrokine-alpha antibody. The invention further relates to screening methods for identifying compounds that inhibit or enhance the action of Neutrokine-alpha. Also provided are diagnostic methods for detecting autoimmune disorders and therapeutic methods for treating autoimmune disorders using a Neutrokine-alpha antibody.Type: GrantFiled: August 27, 2010Date of Patent: July 31, 2012Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni
-
Patent number: 8212004Abstract: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.Type: GrantFiled: February 10, 2005Date of Patent: July 3, 2012Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni
-
Publication number: 20120122762Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.Type: ApplicationFiled: January 26, 2012Publication date: May 17, 2012Applicant: Human Genome Sciences, Inc.Inventors: Steven M. Ruben, Craig A. Rosen, Daniel R. Soppet, Kenneth C. Carter, Daniel P. Bednarik, Gregory A. Endress, Guo-Liang Yu, Jian Ni, Ping Feng, Paul E. Young, John M. Greene, Ann M. Ferrie, D. Roxanne Duan, Jing-Shan Hu, Kimberly A. Florence, Henrik S. Olsen, Carrie L. Fischer, Reinhard Ebner, Laurie A. Brewer, Paul A. Moore, Yanggu Shi, David W. LaFleur, Yi Li, Zhizhen Zeng, Hla Kyaw
-
Patent number: 8173122Abstract: The present invention relates to a novel Neutrokine-alpha, and a splice variant thereof designated Neutrokine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokine-alpha and/or Neutrokine-alphaSV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.Type: GrantFiled: July 9, 2008Date of Patent: May 8, 2012Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni
-
Publication number: 20120045432Abstract: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.Type: ApplicationFiled: November 22, 2010Publication date: February 23, 2012Applicant: HUMAN GENOME SCIENCES, INC.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni
-
Publication number: 20120039890Abstract: The present invention relates to a Neutrokine-alpha antibody and a process for producing a Neutrokine-alpha antibody. The invention further relates to screening methods for identifying compounds that inhibit or enhance the action of Neutrokine-alpha. Also provided are diagnostic methods for detecting autoimmune disorders and therapeutic methods for treating autoimmune disorders using a Neutrokine-alpha antibody.Type: ApplicationFiled: August 27, 2010Publication date: February 16, 2012Applicant: HUMAN GENOME SCIENCES, INC.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni
-
Patent number: 8071092Abstract: The present invention relates to a novel Neutrokine-alpha, and a splice variant thereof designated Neutrokine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokine-alpha and/or Neutrokine-alphaSV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.Type: GrantFiled: June 8, 2000Date of Patent: December 6, 2011Assignee: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni
-
Publication number: 20110256145Abstract: The present invention relates to a novel connective tissue growth factor-3 protein which is a member of the growth factor superfamily. In particular, isolated nucleic acid molecules are provided encoding the human connective tissue growth factor-3 protein. Connective tissue growth factor-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic and therapeutic methods for detecting and treating connective tissue related disorders.Type: ApplicationFiled: June 29, 2011Publication date: October 20, 2011Applicant: Human Genome Sciences, Inc.Inventors: Reinhard Ebner, Arvind Chopra, Steven M. Ruben
-
Patent number: 8003386Abstract: The present invention relates to novel Tumor Necorsis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6? & -6? proteins. TNFR-6? & -6? polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6? & -6? activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.Type: GrantFiled: January 13, 1998Date of Patent: August 23, 2011Assignee: Human Genome Sciences, Inc.Inventors: Reiner Gentz, Reinhard Ebner, Guo-Liang Yu, Steven M. Ruben, Jian Ni, Ping Feng
-
Patent number: 7994284Abstract: The present invention relates to a novel connective tissue growth factor-3 protein which is a member of the growth factor superfamily. In particular, isolated nucleic acid molecules are provided encoding the human connective tissue growth factor-3 protein. Connective tissue growth factor-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic and therapeutic methods for detecting and treating connective tissue related disorders.Type: GrantFiled: April 15, 2010Date of Patent: August 9, 2011Assignee: Human Genome Sciences, Inc.Inventors: Reinhard Ebner, Arvind Chopra, Steven M. Ruben
-
Publication number: 20110165160Abstract: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.Type: ApplicationFiled: December 10, 2010Publication date: July 7, 2011Applicant: HUMAN GENOME SCIENCES, INC.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni
-
Patent number: 7964190Abstract: The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as tumor cell growth.Type: GrantFiled: February 28, 2003Date of Patent: June 21, 2011Assignee: Human Genome Sciences, Inc.Inventors: Reinhard Ebner, Guo-Liang Yu, Steven M Ruben, Yifan Zhai, Stephen Ullrich